Home › Trials › NCT06760273

Long-term effects of inhaled Tobramycin on bronchiectasis patients

Extended Observational Study on the Long-term Impact of Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Patients With Bronchiectasis: The ERASE II Study

Observational Shanghai Pulmonary Hospital, Shanghai, China · NCT06760273

This study is testing the long-term effects of a treatment that clears a specific lung infection in people with bronchiectasis to see how it improves their quality of life and lung health over time.

Quick facts

Study typeObservational
Enrollment364 (estimated)
Ages18 Years to 80 Years
SexAll
SponsorShanghai Pulmonary Hospital, Shanghai, China Academic / other
Locations58 sites (Hefei, Anhui and 57 other locations)
Trial IDNCT06760273 on ClinicalTrials.gov

What this trial studies

The ERASE II study is a prospective observational study that aims to evaluate the long-term impact of successfully eradicating Pseudomonas aeruginosa in patients with bronchiectasis. Following an initial 9-month period of the ERASE study, this study will extend observation for an additional 27 months to assess various outcomes such as quality of life, lung function, and frequency of pulmonary exacerbations. The study will also monitor the incidence of reinfections with Pseudomonas aeruginosa, providing insights into the long-term benefits of eradication therapy.

Who should consider this trial

Good fit: Ideal candidates for this study are adults with bronchiectasis who have participated in the initial ERASE study and provided informed consent.

Not a fit: Patients who were lost to follow-up in the ERASE study or deemed ineligible by the researcher may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could improve the long-term health outcomes and quality of life for patients with bronchiectasis by demonstrating the benefits of eradicating Pseudomonas aeruginosa.

How similar studies have performed: Previous studies have shown promising results in the efficacy of Tobramycin for eradicating Pseudomonas aeruginosa, making this follow-up study a valuable continuation of that research.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* all patients who participate the ERSE study
* write the informed consent form.

Exclusion Criteria:

* patients who were lost of follow up in the ERASE study
* ineligible for inclusion at the discretion of the researcher for other reasons.

Where this trial is running

Hefei, Anhui and 57 other locations

+8 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Bronchiectasis AdultbronchiectasisPseudomonas AeruginosaEradicationLong-term impactObservational study
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.